Context Therapeutics (CNTX) Equity Average (2020 - 2026)

Context Therapeutics has disclosed Equity Average across 7 years of filings, most recently posting $56.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $56.3 million, down 39.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.3 million (down 39.5% YoY), and the FY2025 annual result was $77.9 million, up 45.36% from the prior year.
• Equity Average came in at $56.3 million for Q1 2026 at Context Therapeutics, down from $66.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $93.1 million in Q1 2025 to a low of $10.2 million in Q1 2024.
• The 5-year median for Equity Average is $46.8 million (2022), against an average of $52.3 million.
• Across the five-year window, Equity Average plunged 68.0% in 2024 and soared 816.84% in 2025, its largest moves.
• Context Therapeutics' Equity Average stood at $36.4 million in 2022, then slumped by 58.46% to $15.1 million in 2023, then surged by 492.03% to $89.6 million in 2024, then slipped by 25.39% to $66.8 million in 2025, then declined by 15.69% to $56.3 million in 2026.
• The last three Equity Average figures came in at $56.3 million (Q1 2026), $66.8 million (Q4 2025), and $77.9 million (Q3 2025), per Business Quant data.